OVERCOMING RESISTANCE TO NK-MEDIATED LYSIS IN ENZALUTAMIDE-RESISTANT PROSTATE CANCER CELLS

被引：0
|
作者：
Dahut, Madeline [1 ]
Fousek, Kristen [1 ]
Horn, Lucas [1 ]
Qin, Haiyan [1 ]
Schlom, Jeffrey [1 ]
Palena, Claudia [1 ]
机构：
[1] Natl Canc Inst, Bethesda, MD USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0909
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
909
引用
收藏
页码：A947 / A947
页数：1
相关论文
共 50 条
  • [31] MCT inhibition as a therapeutic strategy to target Enzalutamide-resistant prostate cancer.
    Bhattacharjee, Sayani
    Doan, Jonathan
    Wynn, Rebecca
    Nadiminty, Nagalakshmi
    CANCER RESEARCH, 2021, 81 (13)
  • [32] Multivalent peptoid conjugates suppress enzalutamide-resistant prostate cancer cellular proliferation
    Wang, Yu
    Levine, Paul
    Dehigaspitiya, Dilani
    Profit, Adam
    Logan, Susan
    Imberg-Kazdan, Keren
    Kirshenbaum, Kent
    Garabedian, Michael
    CANCER RESEARCH, 2016, 76
  • [33] Daclatasvir, an Antiviral Drug, Downregulates Tribbles 2 Pseudokinase and Resensitizes Enzalutamide-Resistant Prostate Cancer Cells
    Monga, Jitender
    Valeriote, Frederick
    Hwang, Clara
    Gadgeel, Shirish
    Ghosh, Jagadananda
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (03) : 381 - 392
  • [34] Minnelide reduces castration-resistant and enzalutamide-resistant prostate cancer via downregulation of androgen receptor-mediated signaling
    Isharwal, Sumit
    Modi, Shrey
    Barlass, Usman
    Dudeja, Vikas
    Saluja, Ashok
    Banerjee, Sulagna
    Konety, Badrinath
    CANCER RESEARCH, 2015, 75
  • [35] MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors
    Furlan, Tobias
    Kirchmair, Alexander
    Sampson, Natalie
    Puhr, Martin
    Gruber, Martina
    Trajanoski, Zlatko
    Santer, Frederic R.
    Parson, Walther
    Handle, Florian
    Culig, Zoran
    AMERICAN JOURNAL OF PATHOLOGY, 2021, 191 (06): : 1094 - 1107
  • [36] Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models
    Toren, Paul
    Kim, Soojin
    Cordonnier, Thomas
    Crafter, Claire
    Davies, Barry R.
    Fazli, Ladan
    Gleave, Martin E.
    Zoubeidi, Amina
    EUROPEAN UROLOGY, 2015, 67 (06) : 986 - 990
  • [37] Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer
    Erb, Holger H. H.
    Bodenbender, Julia
    Handle, Florian
    Diehl, Tamara
    Donix, Lukas
    Tsaur, Igor
    Gleave, Martin
    Haferkamp, Axel
    Huber, Johannes
    Fuessel, Susanne
    Juengel, Eva
    Culig, Zoran
    Thomas, Christian
    PLOS ONE, 2020, 15 (08):
  • [38] Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer
    Buttigliero, Consuelo
    Tucci, Marcello
    Bertaglia, Valentina
    Vignani, Francesca
    Bironzo, Paolo
    Di Maio, Massimo
    Scagliotti, Giorgio Vittorio
    CANCER TREATMENT REVIEWS, 2015, 41 (10) : 884 - 892
  • [39] Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer
    Kang, Borui
    Mottamal, Madhusoodanan
    Zhong, Qiu
    Bratton, Melyssa
    Zhang, Changde
    Guo, Shanchun
    Hossain, Ahamed
    Ma, Peng
    Zhang, Qiang
    Wang, Guangdi
    Payton-Stewart, Florastina
    PHARMACEUTICALS, 2023, 16 (05)
  • [40] Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
    Graff, Julie N.
    Alumkal, Joshi J.
    Drake, Charles G.
    Thomas, George V.
    Redmond, William L.
    Farhad, Mohammad
    Cetnar, Jeremy P.
    Ey, Frederick S.
    Bergan, Raymond C.
    Slottke, Rachel
    Beer, Tomasz M.
    ONCOTARGET, 2016, 7 (33) : 52810 - 52817
12345